Biogen to buy Apellis Pharmaceuticals for $5.6 billion in rare disease push

Biogen has agreed to acquire ​Apellis ​Pharmaceuticals ​for about $5.6 billion in cash, expanding its portfolio ⁠of ‌rare-disease medicines.

Please follow us:

This post was originally published here